Consistent with findings from AAV-TBG-Trim26 (△RING) in vivo and in vitro, mice groups injected with AAV-TBG-Trim26 (AXXA) or AAV-TBG-Trim26 (AXXXXA) also failed to mitigate NASH progression (P < 0.05 by one-way ANOVA; Supplementary Fig. 17b–j). This evidence concerns the gene TRIM26 and metabolic dysfunction-associated steatohepatitis.